Frontierby eninvs

Language: EN · RU

← Region

Life Healthcare (LHC) USD

At a glance: strengths & risks
✓Revenue growing (+6%)✓Net cash balance sheet✗Profit falling (-20%)

Sector: Healthcare

ZA_LHC

Price chart

11.55 ZARDay -2.78%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
11.55 ZAR · -2.78%
Market cap
1.0 bn USD

Growth

Δ revenue y/y
14.5%
Δ EBITDA y/y
18.7%

Multiples

P/E (LTM)
2.7x
P/B (FY)
1.6x
P/E (ann.)
11.1x
EV/EBITDA (LTM)
21.8x
EV/EBITDA (ann.)
20.0x

Cash return

Dividend yield
25.4%
FCF yield (LTM)
-26.4%

Value creation

fundamental value/yr, % of market cap
Value created / year
-22.2%
↓ details

Liquidity

Daily turnover (listing)
34.8 mln ZAR

Shares: yahoo_fundamentals_timeseries/LHC.JO

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in M USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueM USDOperating profitM USDD&AM USDEBITDAM USDNet profitM USDOperating CFM USDCapex + M&AM USDAssetsM USDEquityM USDROE (annualized)Net debtM USDSource
2026-03-31H1 2026 (6M)OK758.9
y/y 14.5%
77.9
y/y 22.9%
40.3
y/y 11.3%
118.1
y/y 18.7%
46.6
y/y —
71.0-678.01372.8
y/y 7.0%
699.6
y/y 34.8%
13.7%3683.0Link
2025-09-30H2 2025 (6M)OK724.1
y/y 5.3%
61.9
y/y 4.6%
36.3
y/y 2.6%
98.1
y/y 3.8%
333.3
y/y 333.1%
152.2-1105.01487.2
y/y 4.9%
658.6
y/y -9.8%
36.2%-540.0—
2025-03-31H1 2025 (6M)OK662.7
y/y 9.5%
63.4
y/y 4.3%
36.2
y/y 15.9%
99.6
y/y 8.2%
-119.8
y/y -164.2%
92.3-702.01282.4
y/y -21.6%
519.1
y/y -20.7%
-38.4%3410.0Link
2024-09-30H2 2024 (6M)OK687.6
y/y 11.4%
59.2
y/y 10.1%
35.4
y/y 14.5%
94.5
y/y 11.7%
77.0
y/y 563.1%
104.7-793.01417.7
y/y -41.4%
730.2
y/y -31.9%
38.1%810.0—
2024-03-31H1 2024 (6M)OK604.9
y/y -3.1%
60.7
y/y -13.3%
31.2
y/y 1.2%
92.0
y/y -8.8%
186.6
y/y 500.0%
98.6-573.01634.7
y/y -34.4%
654.8
y/y -45.1%
43.2%-6032.0Link
2023-09-30H2 2023 (6M)OK617.2
y/y —
53.7
y/y —
30.9
y/y —
84.6
y/y —
-16.6
y/y —
206.8-1049.02418.5
y/y —
1071.7
y/y —
1.3%11227.0—
2023-03-31H1 2023 (6M)OK624.6
y/y —
70.0
y/y —
30.9
y/y —
100.9
y/y —
31.1
y/y —
49.3-474.02491.1
y/y —
1193.0
y/y —
—12469.0Link

Revenue & EBITDA

RevenueEBITDA

Quarterly values (ZAR mln)

-20002004006008002023 q12023 q32023 q42024 q12024 q32024 q42025 q12025 q32025 q42026 q1

Year-over-year change

-150%-100%-50%0%2023 q12023 q32023 q42024 q12024 q32024 q42025 q12025 q32025 q42026 q1

Cash flow

FCF (ZAR mln)

-1 500-1 000-50005001 0002023 q12023 q32023 q42024 q12024 q32024 q42025 q12025 q32025 q42026 q1

Net debt / cash (ZAR mln)

-10 000-5 00005 00010 0002023 q12023 q32023 q42024 q12024 q32024 q42025 q12025 q32025 q42026 q1

Profit and cash

Profit is cash-backed
In a typical year of 2022–2025 operating cash flow came to 1.94x of reported net profit; after capex, 1.24x.
year2022202320242025
cash flow / profit2.73x17.69x0.77x1.15x
accruals, % of assets-6.3%-9.7%4.5%-2.2%
Last twelve months (to 2026-03-31): 0.32x of profit came back as operating cash flow.
net debt / EBITDA -0.1x · capex 1.3x of depreciation
● Over the last twelve months operating cash flow covered 32% of profit, against 2x across the annual window.
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -14.2%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-03-31 vs 2025-03-31)
= (118 − 100) × 1.84
9
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (1 033 + 3 683) ÷ 217
21.7x
3. Target multiple
(Current EV/EBITDA + 8) ÷ 2
= (21.7 + 8) ÷ 2
14.9x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= -273 + 0 + 0 − 0
-273
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (9 × 14.9 + -273) ÷ 1 033
-14.2%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • half-year basis (semi-annual reporter)
  • dividends/buybacks not in data - balance cash flow uses net-debt change only
  • growth discounted x0.25: EBITDA grew but net profit FELL while net debt rose - debt-funded growth not reaching equity (interest drag)

Revenue growth & acceleration

Growth steady →
Last-year revenue growth +6% vs +5% the year before — a +1.5 pp move. 3-year CAGR +7%.
revenue growth by year: 2023 +10% · 2024 +5% · 2025 +6%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-06-1723 ZAREx-dividend: 23 ZAR per sharePaidYahoo Finance (ex-div)
2025-12-1735 ZAREx-dividend: 35 ZAR per sharePaidYahoo Finance (ex-div)
2025-09-17235 ZAREx-dividend: 235 ZAR per sharePaidYahoo Finance (ex-div)
2025-06-1121 ZAREx-dividend: 21 ZAR per sharePaidYahoo Finance (ex-div)
2025-01-0870 ZAREx-dividend: 70 ZAR per sharePaidYahoo Finance (ex-div)
2024-12-1131 ZAREx-dividend: 31 ZAR per sharePaidYahoo Finance (ex-div)
2024-06-1219 ZAREx-dividend: 19 ZAR per sharePaidYahoo Finance (ex-div)
2024-04-03600 ZAREx-dividend: 600 ZAR per sharePaidYahoo Finance (ex-div)
2023-12-1227 ZAREx-dividend: 27 ZAR per sharePaidYahoo Finance (ex-div)
2023-06-1317 ZAREx-dividend: 17 ZAR per sharePaidYahoo Finance (ex-div)
2022-12-0725 ZAREx-dividend: 25 ZAR per sharePaidYahoo Finance (ex-div)
2022-06-1415 ZAREx-dividend: 15 ZAR per sharePaidYahoo Finance (ex-div)
2021-12-0825 ZAREx-dividend: 25 ZAR per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Life Healthcare (LHC) — from primary filings.

Life Healthcare operates private hospitals and provides complementary healthcare services in Southern Africa, including mental health, rehabilitation, renal dialysis, oncology, and diagnostics. It also manages long-term care centers for public sector patients and holds rights to distribute molecular imaging products in Africa.

Frequently asked questions

What is Life Healthcare (LHC)'s P/E ratio?
Life Healthcare (LHC) trades at a P/E of 2.7x (price to trailing 12-month earnings).
What is Life Healthcare (LHC)'s EV/EBITDA?
Life Healthcare (LHC) trades at 21.8x EV/EBITDA.
What is Life Healthcare (LHC)'s P/B ratio?
Life Healthcare (LHC) trades at a P/B of 1.6x.
What is Life Healthcare (LHC)'s dividend yield?
Life Healthcare (LHC)'s trailing 12-month dividend yield is 25.4%.
What is Life Healthcare (LHC)'s return on equity (ROE)?
Life Healthcare (LHC)'s ROE is 13.7%.
What is Life Healthcare (LHC)'s market capitalization?
Life Healthcare (LHC)'s market cap is 1.0 bn USD.

See also: South African Stocks (2026): Gold, Cheap Banks and the JSE Discount · The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map